Chester County News and Community Website
Headquartered in Berwyn, PA, Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has significantly bolstered its executive team by welcoming four industry professionals to its ranks. The move highlights Annovis’s efforts to innovative leadership …
Annovis Bio Boosts Executive Team with Four Industry Veterans Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) recently disclosed the encouraging results of its Phase III clinical trial related to Parkinson’s disease treatment. The experimental drug, buntanetap, has shown …
Annovis Bio’s Breakthrough in Parkinson’s Treatment: New Drug Buntanetap Shows Promise Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has filed a provisional patent covering the manufacturing process of novel solid forms of buntanetap. This move aims to strengthen the company’s …
Annovis Bio Files Provisional Patent for New Buntanetap Manufacturing Process Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has filed a new composition of matter patent with the U.S. Patent and Trademark Office. This patent covers novel crystalline forms of …
Annovis Bio Files Patent for New Crystal Form of Buntanetap Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) will host an investor webcast on July 2, 2024, at 4:30 PM ET to discuss recent progress and future plans for its …
Annovis Bio to Host Investor Webcast on Buntanetap Developments Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has been selected to present significant findings from its latest Alzheimer’s study at the Alzheimer’s Association International Conference® 2024 (AAIC®). The conference …
Annovis Bio to Present Pioneering Alzheimer’s Study at International Conference Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced promising results from its recent Phase II/III clinical trial for its lead drug candidate, Buntanetap, targeting Alzheimer’s disease (AD). The …
Annovis Bio’s Alzheimer’s Drug Shows Promise in Phase II/III Trial Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced it will host an investor webcast on June 11, 2024, at 4:30 p.m. ET to discuss recent developments and future plans …
Annovis Bio to Host Investor Webcast on Lead Drug Candidate Buntanetap Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced a significant milestone in its research with the publication of a new article in the journal Biomolecules. The study focuses on …
Annovis Bio Publishes Key Study on Posiphen Drug Across Species Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has made a breakthrough in an ongoing study of Alzheimer’s disease. Their novel Alzheimer’s drug, buntanetap, which specifically targets neurotoxic proteins, has …
Groundbreaking Alzheimer’s Study Reveals Potential for Progression-Slowing Therapy Read More